Literature DB >> 20497196

Steroid minimization for sirolimus-treated renal transplant recipients.

Arthur J Matas1, Darla Granger, Dixon B Kaufman, Minnie M Sarwal, Ronald M Ferguson, E Steve Woodle, John S Gill.   

Abstract

Steroids are associated with a myriad of post-transplant side effects. Therefore, as new immunosuppressive drugs have been developed, attempts have been made to minimize steroid exposure. Sirolimus (SRL) has been demonstrated to have efficacy in early and late post-transplant immunosuppression. Accordingly, numerous trials have studied steroid minimization (early and late post-transplant) in the context of SRL-containing protocols (either with or without a calcineurin inhibitor). We herein review these trials and show that recent studies have determined that both late steroid withdrawal and early rapid discontinuation can be successful with SRL immunosuppression.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497196     DOI: 10.1111/j.1399-0012.2010.01282.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  2 in total

1.  A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.

Authors:  R Brian Stevens; Kirk W Foster; Clifford D Miles; Andre C Kalil; Diana F Florescu; John P Sandoz; Theodore H Rigley; Tamer Malik; Lucile E Wrenshall
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

2.  A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes.

Authors:  R Brian Stevens; Kirk W Foster; Clifford D Miles; James T Lane; Andre C Kalil; Diana F Florescu; John P Sandoz; Theodore H Rigley; Kathleen J Nielsen; Jill Y Skorupa; Anna M Kellogg; Tamer Malik; Lucile E Wrenshall
Journal:  Transplantation       Date:  2015-01       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.